Melanoma is responsible for about 80% of skin cancer deaths worldwide, particularly in cases with metastasis. Melanoma shows resistance to standard therapy and the search for novel treatment options is a medical need.
Researchers from Wenzhou Medical University and affiliated organizations presented the discovery and preclinical characterization of a novel myeloid differentiation primary response 88 (MyD88) inhibitor for the treatment of acute lung injury (ALI).
Myelodysplastic syndromes (MDS) are marked by ineffective hematopoiesis and dysplasia, which elevate the risk of progression to acute myeloid leukemia (AML). The inflammatory environment in MDS alters the bone marrow niche, facilitating the growth of cancerous cells while inhibiting the healthy formation of blood cells.
Immvention Therapeutix Inc. has entered into a collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease and other chronic conditions.
Neuroblastoma is the most common extracranial solid tumor in children and accounts for up to 15% of childhood cancer-related deaths worldwide. Neuroblastoma tumors are characterized by hypoxia, which represents a major challenge in its treatment.
Mitoribosomes are present in the mitochondria of all eukaryotic cells. Their function is to allow the translation of mitochondrial mRNA that exclusively encodes components of the oxidative phosphorylation complexes (OXPHOS).
Immunoprecise Antibodies Ltd. (IPA) has developed a new class of GLP-1 therapies entirely through AI, designed to enhance efficacy, safety, therapy longevity and patient satisfaction for the treatment of diabetes.
Tikun Therapeutics Inc. has obtained U.S. orphan drug and rare pediatric disease designations for its programs in familial dysautonomia, namely its rAAV2-U1a-hELP1 gene replacement therapy for the treatment of optic neuropathy in familial dysautonomia and BPN-36964 for systemic treatment of familial dysautonomia.
Cardiopulmonary resuscitation (CPR) after cardiac arrest (CA) is often a cause of secondary neurological impairment, which results in considerable morbidity and mortality. Suppression of protein degradation of key blood-brain barrier (BBB) components after CPR could maintain the stability of the BBB function, and as such minimize secondary neurological damage and improve long-term prognosis after ischemia reperfusion injury.
RSS
